Vedolizumab as induction and maintenance therapy for Crohn's disease
BACKGROUND: The efficacy of vedolizumab, an α4β 7 integrin antibody, in Crohn's disease is unknown. METHODS: In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with activ
|Collections||ANU Research Publications|
|Source:||New England Journal of Medicine|
|01_Sandborn_Vedolizumab_as_induction_and_2013.pdf||700.22 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.